Breaking Finance News

Maxim Group covered BioLife Solutions (NASDAQ:BLFS), upping its target price to $7.00 today

Just yesterday BioLife Solutions (NASDAQ:BLFS) traded -4.91% lower at $5.29. BLFS’s 50-day average is $4.36 and its two hundred day average is $2.86. With the last close up 76.04% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 868,138 shares of the stock were exchanged, up from an average trading volume of 153,628

Reporting a possible upside of 0.32%, Maxim Group increased the stock price target of BioLife Solutions (NASDAQ:BLFS) to $7.00

Previously on 7/5/2017, Janney Capital released a statement for BioLife Solutions (NASDAQ:BLFS) bumped up the target price from $0.00 to $5.00. At the time, this indicated a possible upside of 0.91%.

Recent Performance Chart

BioLife Solutions (NASDAQ:BLFS)

BioLife Solutions has a one year low of $1.43 and a one year high of $5.91 BLFS’s market cap is currently $0.

General Information About BioLife Solutions (NASDAQ:BLFS)

BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.